Filana Therapeutics Statistics
Total Valuation
FLNA has a market cap or net worth of $81.64 million. The enterprise value is -$13.86 million.
Important Dates
The last earnings date was Thursday, March 12, 2026, before market open.
| Earnings Date | Mar 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
FLNA has 48.31 million shares outstanding. The number of shares has increased by 3.63% in one year.
| Current Share Class | 48.31M |
| Shares Outstanding | 48.31M |
| Shares Change (YoY) | +3.63% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 11.02% |
| Owned by Institutions (%) | 28.61% |
| Float | 42.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.10 |
| P/TBV Ratio | 1.10 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.23
| Current Ratio | 2.23 |
| Quick Ratio | 2.18 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -82.66% and return on invested capital (ROIC) is -34.13%.
| Return on Equity (ROE) | -82.66% |
| Return on Assets (ROA) | -27.23% |
| Return on Invested Capital (ROIC) | -34.13% |
| Return on Capital Employed (ROCE) | -80.63% |
| Weighted Average Cost of Capital (WACC) | -0.37% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$4.55M |
| Employee Count | 20 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +2.42% in the last 52 weeks. The beta is -0.84, so FLNA's price volatility has been lower than the market average.
| Beta (5Y) | -0.84 |
| 52-Week Price Change | +2.42% |
| 50-Day Moving Average | 2.05 |
| 200-Day Moving Average | 2.50 |
| Relative Strength Index (RSI) | 37.87 |
| Average Volume (20 Days) | 602,327 |
Short Selling Information
The latest short interest is 7.32 million, so 15.14% of the outstanding shares have been sold short.
| Short Interest | 7.32M |
| Short Previous Month | 6.96M |
| Short % of Shares Out | 15.14% |
| Short % of Float | 17.02% |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | -26.59M |
| Operating Income | -60.09M |
| Pretax Income | -90.97M |
| Net Income | -90.97M |
| EBITDA | -59.15M |
| EBIT | -60.09M |
| Earnings Per Share (EPS) | -$1.88 |
Full Income StatementBalance Sheet
The company has $95.50 million in cash and n/a in debt, with a net cash position of $95.50 million or $1.98 per share.
| Cash & Cash Equivalents | 95.50M |
| Total Debt | n/a |
| Net Cash | 95.50M |
| Net Cash Per Share | $1.98 |
| Equity (Book Value) | 74.40M |
| Book Value Per Share | 1.54 |
| Working Capital | 53.88M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$32.25 million and capital expenditures -$581,000, giving a free cash flow of -$32.83 million.
| Operating Cash Flow | -32.25M |
| Capital Expenditures | -581,000 |
| Depreciation & Amortization | 936,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -32.83M |
| FCF Per Share | -$0.68 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
